Correlation of in vivo bioavailability data with an acute pharmacological effect or clinical evidence of safety and effectiveness may be required if needed to establish the clinical significance of a special claim, e.g., in the case of an extended release preparation. [42 FR 1648, Jan. 7, 1977, as amended at 67 FR 77674, Dec. 19, 2002]